Genetic and molecular determinants of prostate cancer among Iranian patients: An update

References

• Kopper L, Timar J. Genomics of prostate cancer: is there anything to “translate”? Pathol Oncol Res. 2005;11:197–203.
   PubMed Web of Science ®Google Scholar
• Sadjadi A, Nooraie M, Ghorbani A. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med. 2007;10:481–485.
   PubMed Web of Science ®Google Scholar
• Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46:3040–3052.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Hosseini SY, Danesh AK, Parvin M, et al. Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men. Int Braz J Urol. 2007;33:167–173.
   PubMedGoogle Scholar
• Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate Int. 2018;6:41–45.
   PubMed Web of Science ®Google Scholar
• Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, et al. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int. 2015;3:135–140.
   PubMed Web of Science ®Google Scholar
• Pourmand G, Salem S, Mehrsai A, et al. The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev. 2007;8:422–428.
   PubMed Web of Science ®Google Scholar
• Bratt O, Kristoffersson U, Lundgren R, et al. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer. 1999;35:272–277.
   PubMed Web of Science ®Google Scholar
• Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993;150:797–802.
   PubMed Web of Science ®Google Scholar
• Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47.
   PubMed Web of Science ®Google Scholar
• Irvine RA, Yu MC, Ross RK, et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995;55:1937–1940.
   PubMed Web of Science ®Google Scholar
• Corder EH, Friedman GD, Vogelman JH, et al. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev. 1995;4:655.
   PubMed Web of Science ®Google Scholar
• Reichardt JK, Makridakis N, Henderson BE, et al. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995;55:3973–3975.
   PubMed Web of Science ®Google Scholar
• Castillejos-Molina R, Rodriguez-Covarrubias F, Sotomayor M, et al. Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Urol Int. 2011;87:270–275.
   PubMed Web of Science ®Google Scholar
• Hasenoehrl T, Keilani M, Sedghi Komanadj T, et al. The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review. Support Care Cancer. 2015;23:2479–2497.
   PubMed Web of Science ®Google Scholar
• Lin PH, Aronson W, Freedland SJ. Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Med. 2015;13:3.
   PubMed Web of Science ®Google Scholar
• Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev. 2001;23:72–81.
   PubMed Web of Science ®Google Scholar
• Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6:87–95.
   PubMedGoogle Scholar
• Cao DL, Ye DW, Zhu Y, et al. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis. 2011;14:166–172.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161.
   PubMed Web of Science ®Google Scholar
• Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77:1265 e9–16.
   Web of Science ®Google Scholar
• Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014;192:1081–1087.
   PubMed Web of Science ®Google Scholar
• Kvitko K, Nunes JC, Weimer TA, et al. Cytochrome P4501A1 polymorphisms in South American Indians. Hum Biol. 2000;72:1039–1043.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Shafiei N, Safarinejad SH. Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, GSTP1) and prostate cancer: a case-control study in Tehran, Iran. Prostate Cancer Prostatic Dis. 2011;14:105–113.
   PubMed Web of Science ®Google Scholar
• Gill JG, Piskounova E, Morrison SJ. Cancer, oxidative stress, and metastasis. Cold Spring Harb Symp Quant Biol. 2016;81:163–175.
   PubMedGoogle Scholar
• Ogawa K, Sun J, Taketani S, et al. Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J. 2001;20:2835–2843.
   PubMed Web of Science ®Google Scholar
• Yun J, Frankenberger CA, Kuo WL, et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J. 2011;30:4500–4514.
   PubMed Web of Science ®Google Scholar
• Ishii T, Itoh K, Takahashi S, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem. 2000;275:16023–16029.
   PubMed Web of Science ®Google Scholar
• Shajari N, Davudian S, Kazemi T, et al. Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression. Artif Cells Nanomed Biotechnol. 2018;46:1495–1504.
   PubMed Web of Science ®Google Scholar
• Neer EJ. Heterotrimeric G proteins: organizers of transmembrane signals. Cell. 1995;80:249–257.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Siwko S, Liu M. Prostate-specific G-protein coupled receptor, an emerging biomarker regulating inflammation and prostate cancer invasion. CMM. 2016;16:526–532.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Siwko S, Zeng L, et al. Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression. Oncogene. 2016;35:1153–1162.
   PubMed Web of Science ®Google Scholar
• Liang F, Yue J, Wang J, et al. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway. Med Oncol. 2015;32:49.
   PubMed Web of Science ®Google Scholar
• Luo W, Tan P, Rodriguez M, et al. Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition. J Biol Chem. 2017; Sep 15292:15525–15537.
   PubMed Web of Science ®Google Scholar
• Zhou C, Dai X, Chen Y, et al. G protein-coupled receptor GPR160 is associated with apoptosis and cell cycle arrest of prostate cancer cells. Oncotarget. 2016;7:12823–12839.
   PubMedGoogle Scholar
• Levine MA, Modi WS, O'Brien SJ. Chromosomal localization of the genes encoding two forms of the G protein beta polypeptide, beta 1 and beta 3, in man. Genomics. 1990;8:380–386.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Safarinejad S, Shafiei N, et al. G Protein β3 subunit gene C825T polymorphism and its association with the presence and clinicopathological characteristics of prostate cancer. J Urol. 2012;188:287–293.
   PubMed Web of Science ®Google Scholar
• Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene. 2007;26:3227–3239.
   PubMed Web of Science ®Google Scholar
• Chambard JC, Lefloch R, Pouyssegur J, et al. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007;1773:1299–1310.
   PubMed Web of Science ®Google Scholar
• Mertens-Walker I, Fernandini BC, Maharaj MS, et al. The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-beta8 in prostate cancer cells. BMC Cancer. 2015;15:164.
   PubMed Web of Science ®Google Scholar
• Bansal N, Mishra PJ, Stein M, et al. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget. 2015;6:15321–15331.
   PubMedGoogle Scholar
• Liu L, Xu C, Hsieh JT, et al. DAB2IP in cancer. Oncotarget. 2016;7:3766–3776.
   PubMedGoogle Scholar
• Fritzsche S, Kenzelmann M, Hoffmann MJ, et al. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer. 2006;13:839–849.
   PubMed Web of Science ®Google Scholar
• Samadaian N, Salehipour P, Ayati M, et al. A potential clinical significance of DAB2IP and SPRY2 transcript variants in prostate cancer. Pathol Res Pract. 2018;214:2018–2024.
   PubMed Web of Science ®Google Scholar
• Zahir ST, Tafti HF, Rahmani K. Overexpression of HER-2/neu in patients with prostatic adenocarcinoma. Asian Pac J Cancer Prev. 2014;15:6425–6428.
   PubMedGoogle Scholar
• Day KC, Lorenzatti Hiles G, Kozminsky M, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Res. 2017;77:74–85.
   PubMed Web of Science ®Google Scholar
• Wen Y, Hu MC, Makino K, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000;60:6841–6845.
   PubMed Web of Science ®Google Scholar
• Tan X, Sun Y, Thapa N, et al. LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. EMBO J. 2015;34:475–490.
   PubMed Web of Science ®Google Scholar
• Li L, Shan Y, Yang H, et al. Upregulation of LAPTM4B-35 promotes malignant transformation and tumorigenesis in L02 human liver cell line. Anat Rec. 2011;294:1135–1142.
   Google Scholar
• Li L, Wei XH, Pan YP, et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene. 2010;29:5785–5795.
   PubMed Web of Science ®Google Scholar
• Yang H, Xiong F, Qi R, et al. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol. 2010;101:363–369.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Rezaei M, Narouie B, et al. Association between LAPTM4B gene polymorphism and prostate cancer susceptibility in an Iranian population. Mol Cell Oncol. 2016;3:e1169342.
   PubMed Web of Science ®Google Scholar
• Zhang H, Qi S, Zhang T, et al. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget. 2015;6:6092–6104.
   PubMedGoogle Scholar
• Ameri A, Alidoosti A, Hosseini SY, et al. Prognostic value of promoter hypermethylation of retinoic acid receptor beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer. Chin J Cancer Res. 2011;23:306–311.
   PubMed Web of Science ®Google Scholar
• Tang D, Kryvenko ON, Mitrache N, et al. Methylation of the RARB gene increases prostate cancer risk in black Americans. J Urol. 2013;190:317–324.
   PubMed Web of Science ®Google Scholar
• Sun H, Lesche R, Li DM, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA. 1999;96:6199–6204.
   PubMed Web of Science ®Google Scholar
• Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7:193–204.
   PubMed Web of Science ®Google Scholar
• Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer. 2007;97:678–685.
   PubMed Web of Science ®Google Scholar
• Fallahabadi ZR, Noori Daloii MR, Mahdian R, et al. Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer. Gene. 2016;575:755–760.
   PubMed Web of Science ®Google Scholar
• Torabi-Nezhad S, Malekmakan L, Mashayekhi M, et al. Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63. Prostate. 2016;76:394–401.
   PubMed Web of Science ®Google Scholar
• Conley-LaComb MK, Saliganan A, Kandagatla P, et al. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling. Mol Cancer. 2013;12:85.
   PubMed Web of Science ®Google Scholar
• Wu Z, Cho H, Hampton GM, et al. Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. Neoplasia. 2009;11:66–76.
   PubMed Web of Science ®Google Scholar
• Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene. 2002;21:319–327.
   PubMed Web of Science ®Google Scholar
• Li P, Nicosia SV, Bai W. Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem. 2001;276:20444–20450.
   PubMed Web of Science ®Google Scholar
• Kimbrough-Allah MN, Millena AC, Khan SA. Differential role of PTEN in transforming growth factor β (TGF-β) effects on proliferation and migration in prostate cancer cells. Prostate. 2018;78:377–389.
   PubMed Web of Science ®Google Scholar
• Preece DM, Harvey JM, Bentel JM, et al. ETS1 regulates NKX3.1 5' promoter activity and expression in prostate cancer cells. Prostate. 2011;71:403–414.
   PubMed Web of Science ®Google Scholar
• Yu CX, Jin T, Chen WW, et al. Identification of Sp1-elements in the promoter region of human homeobox gene NKX3.1. Mol Biol Rep. 2009;36:2353–2360.
   PubMed Web of Science ®Google Scholar
• Kruithof-de Julio M, Shibata M, Desai N, et al. Canonical Wnt signaling regulates Nkx3.1 expression and luminal epithelial differentiation during prostate organogenesis. Dev Dyn. 2013;242:1160–1171.
   PubMed Web of Science ®Google Scholar
• Nodouzi V, Nowroozi M, Hashemi M, et al. Concurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate Cancer. Int Braz J Urol. 2015;41:898–905.
   PubMed Web of Science ®Google Scholar
• Logan M, Anderson PD, Saab ST, et al. RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis. Am J Pathol. 2013;183:951–963.
   PubMed Web of Science ®Google Scholar
• Eide T, Ramberg H, Glackin C, et al. TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells. Cancer Cell Int. 2013;13:4.
   PubMed Web of Science ®Google Scholar
• Erbaykent-Tepedelen B, Karamil S, Gonen-Korkmaz C, et al. DNA damage response (DDR) via NKX3.1 expression in prostate cells. J Steroid Biochem Mol Biol. 2014;141:26–36.
   PubMed Web of Science ®Google Scholar
• Zhang H, Muders MH, Li J, et al. Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res. 2008;68:8770–8778.
   PubMed Web of Science ®Google Scholar
• Moghbeli M, Moghbeli F, Forghanifard MM, et al. Cancer stem cell detection and isolation. Med Oncol. 2014;31:69.
   PubMed Web of Science ®Google Scholar
• Amini S, Fathi F, Mobalegi J, et al. The expressions of stem cell markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3, Dppa4, and Esrrb in bladder, colon, and prostate cancer, and certain cancer cell lines. Anat Cell Biol. 2014;47:1–11.
   PubMedGoogle Scholar
• Jeter CR, Liu B, Lu Y, et al. NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discov. 2016;2:16041.
   PubMed Web of Science ®Google Scholar
• Sheikhi A, Jafarzadeh A, Kokhaei P, et al. Whole tumor cell vaccine adjuvants: comparing IL-12 to IL-2 and IL-15. Iran J Immunol. 2016;13:148–166.
   PubMed Web of Science ®Google Scholar
• Puhr M, De Marzo A, Isaacs W, et al. Inflammation, Microbiota, and Prostate Cancer. Eur Urol Focus. 2016;2:374–382.
   PubMedGoogle Scholar
• Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. FEBS J. 2016;283:2731–2748.
   PubMed Web of Science ®Google Scholar
• Singer BD, King LS, D'Alessio FR. Regulatory T cells as immunotherapy. Front Immunol. 2014;5:46.
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines. 2016;4:pii: E28.
   Web of Science ®Google Scholar
• Jafarzadeh A, Jamali M, Mahdavi R, et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program. J Mol Neurosci. 2015;55:891–897.
   PubMed Web of Science ®Google Scholar
• Chatrabnous N, Ghaderi A, Ariafar A, et al. Serum concentration of interleukin-35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer. Cytokine. 2019;113:221–227.
   PubMed Web of Science ®Google Scholar
• Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. Nat Immunol. 2016;17:906–913.
   PubMed Web of Science ®Google Scholar
• Kelly PN, Romero DL, Yang Y, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015;212:2189–2201.
   PubMed Web of Science ®Google Scholar
• Inoue A, Obayashi K, Sonoda Y, et al. Regulation of matrix metalloproteinase-1 and alpha-smooth muscle actin expression by interleukin-1 alpha and tumour necrosis factor alpha in hepatic stellate cells. Cytotechnology. 2017;69:461–468.
   PubMed Web of Science ®Google Scholar
• Kwon MJ, Hong E, Choi Y, et al. Interleukin-1alpha promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression. Biochem Biophys Res Commun. 2014;446:487–492.
   PubMed Web of Science ®Google Scholar
• Mar AC, Chu CH, Lee HJ, et al. Interleukin-1 receptor type 2 acts with c-Fos to enhance the expression of Interleukin-6 and vascular endothelial growth factor A in colon cancer cells and induce angiogenesis. J Biol Chem. 2015;290:22212–22224.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Bahari G, Sarhadi S, et al. 4-bp insertion/deletion (rs3783553) polymorphism within the 3'UTR of IL1A contributes to the risk of prostate cancer in a sample of Iranian population. J Cell Biochem. 2018;119:2627–2635.
   PubMed Web of Science ®Google Scholar
• Kim KW, Kim HR. Macrophage migration inhibitory factor: a potential therapeutic target for rheumatoid arthritis. Korean J Intern Med. 2016;31:634–642.
   PubMed Web of Science ®Google Scholar
• Lue H, Kleemann R, Calandra T, et al. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect. 2002;4:449–460.
   PubMed Web of Science ®Google Scholar
• Razzaghi MR, Mazloomfard MM, Malekian S, et al. Association of macrophage inhibitory factor -173 gene polymorphism with biological behavior of prostate cancer. Urol J. 2019;16:32–36.
   PubMed Web of Science ®Google Scholar
• Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014;113:986–992.
   PubMed Web of Science ®Google Scholar
• Taheri M, Noroozi R, Rakhshan A, et al. IL-6 genomic variants and risk of prostate cancer. Urol J. 2018. DOI:10.22037/uj.v0i0.4543
   PubMedGoogle Scholar
• Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. 2012;360:52–58.
   PubMed Web of Science ®Google Scholar
• Dargahi Abbasabad G, Banan Khojasteh SM, Eskandari Naji H, et al. An interleukin-6 single nucleotide polymorphism and susceptibility to prostate adenocarcinoma and bone metastasis in an iranian population. Asian Pac J Cancer Prev. 2018;19:1717–1720.
   PubMedGoogle Scholar
• Kotipatruni RR, Nalla AK, Asuthkar S, et al. Apoptosis induced by knockdown of uPAR and MMP-9 is mediated by inactivation of EGFR/STAT3 signaling in medulloblastoma. PLoS One. 2012;7:e44798.
   PubMed Web of Science ®Google Scholar
• Soleimanpour E, Babaei E. Survivin as a potential target for cancer therapy. Asian Pac J Cancer Prev. 2015;16:6187–6191.
   PubMedGoogle Scholar
• Karimian M, Aftabi Y, Mazoochi T, et al. Survivin polymorphisms and susceptibility to prostate cancer: A genetic association study and an in silico analysis. EXCLI J. 2018;17:479–491.
   PubMed Web of Science ®Google Scholar
• Eslami M, Khamechian T, Mazoochi T, et al. Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy. Springerplus. 2016;5:621.
   PubMedGoogle Scholar
• Behfarjam F, Rostamzadeh J, Zarei MA, et al. Association of two polymorphic codons in P53 and ABCC1 promoter with prostate cancer. Iran J Biotechnol. 2015;13:49–54.
   PubMed Web of Science ®Google Scholar
• Babaei F, Ahmadi SA, Abiri R, et al. The TP53 Codon 72 polymorphism and risk of sporadic prostate cancer among Iranian patients. Iran J Public Health. 2014;43:453–459.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Amininia S, Ebrahimi M, et al. Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncol Lett. 2017;13:2483–2489.
   PubMed Web of Science ®Google Scholar
• Basudhar D, Somasundaram V, de Oliveira GA, et al. Nitric oxide synthase-2-derived nitric oxide drives multiple pathways of breast cancer progression. Antioxid Redox Signal. 2017;26:1044–1058.
   PubMed Web of Science ®Google Scholar
• Li LM, Kilbourn RG, Adams J, et al. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res. 1991;51:2531–2535.
   PubMed Web of Science ®Google Scholar
• Yoshie Y, Ohshima H. Synergistic induction of DNA strand breakage by catechol-estrogen and nitric oxide: implications for hormonal carcinogenesis. Free Radic Biol Med. 1998;24:341–348.
   PubMed Web of Science ®Google Scholar
• Calmels S, Hainaut P, Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res. 1997;57:3365–3369.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Safarinejad S, Shafiei N, et al. Effects of the T-786C, G894T, and intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol. 2013;31:1132–1140.
   PubMed Web of Science ®Google Scholar
• Wilding G. The importance of steroid hormones in prostate cancer. Cancer Surv. 1992;14:113–130.
   PubMedGoogle Scholar
• Bauman DR, Steckelbroeck S, Peehl DM, et al. Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology. 2006;147:5806–5816.
   PubMed Web of Science ®Google Scholar
• Gauthier-Landry L, Bélanger A, Barbier O. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution. J Steroid Biochem Mol Biol. 2015;145:187–192.
   PubMed Web of Science ®Google Scholar
• Rane A, Ekstrom L. Androgens and doping tests: genetic variation and pit-falls. Br J Clin Pharmacol. 2012;74:3–15.
   PubMed Web of Science ®Google Scholar
• Wei Q, Galbenus R, Raza A, et al. Androgen-stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels. Cancer Res. 2009;69:2332–2339.
   PubMed Web of Science ®Google Scholar
• Habibi M, Mirfakhraie R, Khani M, et al. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: a case-control study. Gene. 2017;634:47–52.
   PubMed Web of Science ®Google Scholar
• Amirghofran Z, Monabati A, Gholijani N. Androgen receptor expression in relation to apoptosis and the expression of cell cycle related proteins in prostate cancer. Pathol Oncol Res. 2004;10:37–41.
   PubMed Web of Science ®Google Scholar
• Barnes HJ, Arlotto MP, Waterman MR. Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli. Proc Natl Acad Sci U S A. 1991;88:5597–5601.
   PubMed Web of Science ®Google Scholar
• Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994;3:1873–1876.
   PubMed Web of Science ®Google Scholar
• Karimpur-Zahmatkesh A, Farzaneh F, Pouresmaeili F, et al. A2 allele polymorphism of the CYP17 gene and prostate cancer risk in an iranian population. Asian Pac J Cancer Prev. 2013;14:1049–1052.
   PubMedGoogle Scholar
• Ho SM, Leung YK, Chung I. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann N Y Acad Sci. 2006;1089:177–193.
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS letters. 1997;410:87–90.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Safarinejad S, Shafiei N, et al. Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog. 2012;51:E104–E117.
   PubMed Web of Science ®Google Scholar
• Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998;95:1735–1740.
   PubMed Web of Science ®Google Scholar
• Saeki N, Gu J, Yoshida T, et al. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin Cancer Res. 2010;16:3533–3538.
   PubMed Web of Science ®Google Scholar
• Taeb J, Asgari M, Abolhasani M, et al. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients. Pathol Res Pract. 2014;210:18–23.
   PubMed Web of Science ®Google Scholar
• Iranpour M, Soudyab M, Geranpayeh L, et al. Expression analysis of four long noncoding RNAs in breast cancer. Tumour Biol. 2016;37:2933–2940.
   PubMedGoogle Scholar
• Xue B, He L. An expanding universe of the non-coding genome in cancer biology. Carcinogenesis. 2014;35:1209–1216.
   PubMed Web of Science ®Google Scholar
• Kino T, Hurt DE, Ichijo T, et al. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal. 2010;3:ra8.
   PubMed Web of Science ®Google Scholar
• Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10:925–933.
   PubMed Web of Science ®Google Scholar
• Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15:7–21.
   PubMed Web of Science ®Google Scholar
• Grote P, Herrmann BG. The long non-coding RNA Fendrr links epigenetic control mechanisms to gene regulatory networks in mammalian embryogenesis. RNA Biol. 2013;10:1579–1585.
   PubMed Web of Science ®Google Scholar
• Li Z, Rana TM. Decoding the noncoding: prospective of lncRNA-mediated innate immune regulation. RNA Biol. 2014;11:979–985.
   PubMed Web of Science ®Google Scholar
• Zhang A, Zhao JC, Kim J, et al. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. Cell Rep. 2015;13:209–221.
   PubMed Web of Science ®Google Scholar
• Taheri M, Habibi M, Noroozi R, et al. HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. Gene. 2017;613:20–24.
   PubMed Web of Science ®Google Scholar
• Dinger ME, Amaral PP, Mercer TR, et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008;18:1433–1445.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689–693.
   PubMed Web of Science ®Google Scholar
• Bayat H, Narouie B, Ziaee SM, et al. Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer. Prostate. 2018;78:812–818.
   PubMed Web of Science ®Google Scholar
• Taheri M, Pouresmaeili F, Omrani MD, et al. Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. Biomarkers Med. 2017;11:413–422.
   PubMed Web of Science ®Google Scholar
• Yang L, Lin C, Jin C, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013;500:598–602.
   PubMed Web of Science ®Google Scholar
• Sattarifard H, Hashemi M, Hassanzarei S, et al. Association between genetic polymorphisms of long non-coding RNA PRNCR1 and prostate cancer risk in a sample of the Iranian population. Mol Clin Onc. 2017;7:1152–1158.
   PubMed Web of Science ®Google Scholar
• Cai Y, Yu X, Hu S, et al. A brief review on the mechanisms of miRNA regulation. Genom Proteom Bioinfo. 2009;7:147–154.
   PubMedGoogle Scholar
• Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635–647.
   PubMed Web of Science ®Google Scholar
• Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315:1576–1579.
   PubMed Web of Science ®Google Scholar
• Saffari M, Ghaderian SMH, Omrani MD, et al. The Association of miR-let 7b and miR-548 with PTEN in Prostate Cancer. Urol J. 2019;16:267–273.
   PubMed Web of Science ®Google Scholar
• Houston SI, McManus KJ, Adams MM, et al. Catalytic function of the PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for mitotic entry and genomic stability. J Biol Chem. 2008;283:19478–19488.
   PubMed Web of Science ®Google Scholar
• Wu S, Wang W, Kong X, et al. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev. 2010;24:2531–2542.
   PubMed Web of Science ®Google Scholar
• Beck DB, Oda H, Shen SS, et al. PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes Dev. 2012;26:325–337.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun L, Zhang Y, et al. The histone modifications governing TFF1 transcription mediated by estrogen receptor. J Biol Chem. 2011;286:13925–13936.
   PubMed Web of Science ®Google Scholar
• Shi X, Kachirskaia I, Yamaguchi H, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007;27:636–646.
   PubMed Web of Science ®Google Scholar
• Yang F, Sun L, Li Q, et al. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 2012;31:110–123.
   PubMed Web of Science ®Google Scholar
• Narouie B, Ziaee SAM, Basiri A, et al. Functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene increased the risk of prostate cancer in a sample of Iranian population. Gene. 2017;626:354–357.
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658.
   PubMed Web of Science ®Google Scholar
• Bonci D, Coppola V, Patrizii M, et al. A microRNA code for prostate cancer metastasis. Oncogene. 2016;35:1180–1192.
   PubMed Web of Science ®Google Scholar
• Ghorbanmehr N, Gharbi S, Korsching E, et al. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. Prostate. 2019;79:88–95.
   PubMed Web of Science ®Google Scholar
• Harrison DA. The Jak/STAT pathway. Cold Spring Harb Perspect Biol. 2012;4:a011205.
   PubMed Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–549.
   PubMed Web of Science ®Google Scholar
• Aghaee-Bakhtiari SH, Arefian E, Naderi M, et al. MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches. Tumour Biol. 2015;36:4203–4212.
   PubMedGoogle Scholar
• Wang J, Jia Z, Zhang C, et al. miR-499 protects cardiomyocytes from H 2O 2-induced apoptosis via its effects on Pdcd4 and Pacs2. RNA Biol. 2014;11:339–350.
   PubMed Web of Science ®Google Scholar
• van den Bosch MW, Palsson-Mcdermott E, Johnson DS, et al. LPS induces the degradation of programmed cell death protein 4 (PDCD4) to release Twist2, activating c-Maf transcription to promote interleukin-10 production. J Biol Chem. 2014;289:22980–22990.
   PubMed Web of Science ®Google Scholar
• Lo Furno D, Graziano AC, Caggia S, et al. Decrease of apoptosis markers during adipogenic differentiation of mesenchymal stem cells from human adipose tissue. Apoptosis. 2013;18:578–588.
   PubMed Web of Science ®Google Scholar
• Wu J, Yue B, Lan X, et al. MiR-499 regulates myoblast proliferation and differentiation by targeting transforming growth factor β receptor 1. J Cell Physiol. 2019;234:2523–2536.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Moradi N, Ziaee SA, et al. Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. J Adv Res. 2016;7:491–498.
   PubMed Web of Science ®Google Scholar
• Wang C, Li L, Yin Z, et al. An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma. Carcinogenesis. 2017;38:168–176.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Bahari G, Sattarifard H, et al. Evaluation of a 3-base pair indel polymorphism within pre-microRNA-3131 in patients with prostate cancer using mismatch polymerase chain reaction-restriction fragment length polymorphism. Mol Clin Oncol. 2017;7:696–700.
   PubMed Web of Science ®Google Scholar
• Martinez Y, Li X, Liu G, et al. The role of methionine on metabolism, oxidative stress, and diseases. Amino Acids. 2017;49:2091–2098.
   PubMed Web of Science ®Google Scholar
• Kim KC, Friso S, Choi SW. DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J Nutr Biochem. 2009;20:917–926.
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Hosseinzadeh Colagar A, Karimian M. Association of human methionine synthase-A2756G transition with prostate cancer: a case-control study and in silico analysis. Acta Med Iran. 2017;55:297–303.
   PubMedGoogle Scholar
• Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113.
   PubMed Web of Science ®Google Scholar
• Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37–46.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR, Shafiei N, Safarinejad S. Relationship between three polymorphisms of methylenetetrahydrofolate reductase (MTHFR C677T, A1298C, and G1793A) gene and risk of prostate cancer: a case-control study. Prostate. 2010;70:1645–1657.
   PubMed Web of Science ®Google Scholar
• Moghbeli M, Moaven O, Dadkhah E, et al. High frequency of microsatellite instability in sporadic colorectal cancer patients in Iran. Genet Mol Res. 2011;10:3520–3529.
   PubMed Web of Science ®Google Scholar
• Jafary F, Salehi M, Sedghi M, et al. Association between mismatch repair gene MSH3 codons 1036 and 222 polymorphisms and sporadic prostate cancer in the Iranian population. Asian Pac J Cancer Prev. 2012;13:6055–6057.
   PubMedGoogle Scholar
• Davies MA, Koul D, Dhesi H, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res. 1999;59:2551–2556.
   PubMed Web of Science ®Google Scholar
• Furnari FB, Huang HJ, Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 1998;58:5002–5008.
   PubMed Web of Science ®Google Scholar
• Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA. 2000;97:3207–3212.
   PubMed Web of Science ®Google Scholar
• Pourmand G, Ziaee AA, Abedi AR, et al. Role of PTEN gene in progression of prostate cancer. Urol J. 2007;4:95–100.
   PubMedGoogle Scholar
• Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med. 2009;12:395–404.
   PubMed Web of Science ®Google Scholar
• Parmigiani RB, Bettoni F, Grosso DM, et al. Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int J Cancer. 2008;122:2385–2390.
   PubMed Web of Science ®Google Scholar
• Donkor FF, Monnich M, Czirr E, et al. Outer dense fibre protein 2 (ODF2) is a self-interacting centrosomal protein with affinity for microtubules. J Cell Sci. 2004;117:4643–4651.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Ousati Ashtiani Z, Sabah Golian B, et al. Expression of two testis-specific genes, SPATA19 and LEMD1, in prostate cancer. Arch Med Res. 2010;41:195–200.
   PubMed Web of Science ®Google Scholar
• Blanco-Arias P, Sargent CA, Affara NA. The human-specific Yp11.2/Xq21.3 homology block encodes a potentially functional testis-specific TGIF-like retroposon. Mamm Genome. 2002;13:463–468.
   PubMed Web of Science ®Google Scholar
• Mobini GR, Ghahremani MH, Amanpour S, et al. Transforming Growth Factor Beta-Induced Factor 2-Linked X (TGIF2LX) Regulates Two Morphogenesis Genes, Nir1 and Nir2 in Human Colorectal. Acta Med Iran. 2016;54:302–307.
   PubMedGoogle Scholar
• Ousati Ashtiani Z, Ayati M, Modarresi MH, et al. Association of TGIFLX/Y mRNA expression with prostate cancer. Med Oncol. 2009;26:73–77.
   PubMed Web of Science ®Google Scholar
• Lanza F, Healy L, Sutherland DR. Structural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents. 2001;15:1–13.
   PubMed Web of Science ®Google Scholar
• Sidney LE, Branch MJ, Dunphy SE, et al. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32:1380–1389.
   PubMed Web of Science ®Google Scholar
• Edling CE, Hallberg B. c-Kit–a hematopoietic cell essential receptor tyrosine kinase. Int J Biochem Cell Biol. 2007;39:1995–1998.
   PubMed Web of Science ®Google Scholar
• Krams M, Parwaresch R, Sipos B, et al. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene. 2004;23:588–595.
   PubMed Web of Science ®Google Scholar
• Foroozan M, Roudi R, Abolhasani M, et al. Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. Pathol Res Pract. 2017;213:612–618.
   PubMed Web of Science ®Google Scholar
• Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.
   PubMed Web of Science ®Google Scholar
• Singh S, Singh UP, Grizzle WE, et al. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004;84:1666–1676.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16:2927–2931.
   PubMed Web of Science ®Google Scholar
• Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267:226–244.
   PubMed Web of Science ®Google Scholar
• Dehghani M, Kianpour S, Zangeneh A, et al. CXCL12 modulates prostate cancer cell adhesion by altering the levels or activities of β1-containing integrins. Int J Cell Biol. 2014;2014:981750.
   PubMedGoogle Scholar
• Patrawala L, Calhoun-Davis T, Schneider-Broussard R, et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44 + alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007;67:6796–6805.
   PubMed Web of Science ®Google Scholar
• Mak AB, Pehar M, Nixon AM, et al. Post-translational regulation of CD133 by ATase1/ATase2-mediated lysine acetylation. J Mol Biol. 2014;426:2175–2182.
   PubMed Web of Science ®Google Scholar
• Kalantari E, Asgari M, Nikpanah S, et al. Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res. 2017;23:793–802.
   PubMed Web of Science ®Google Scholar
• Corn PG, Smith BD, Ruckdeschel ES, et al. E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. Clin Cancer Res. 2000;6:4243–4248.
   PubMed Web of Science ®Google Scholar
• Tai KY, Shiah SG, Shieh YS, et al. DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression. Oncogene. 2007;26:3989–3997.
   PubMed Web of Science ®Google Scholar
• Mostafavi-Pour Z, Kianpour S, Dehghani M, et al. Methylation of Integrin α4 and E-cadherin genes in human prostate cancer. Pathol Oncol Res. 2015;21:921–927.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li Z, Guo L, et al. MAGI-2 Inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Arch Biochem Biophys. 2007;467:1–9.
   PubMed Web of Science ®Google Scholar
• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–562.
   PubMed Web of Science ®Google Scholar
• Tolkacheva T, Boddapati M, Sanfiz A, et al. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001;61:4985–4989.
   PubMed Web of Science ®Google Scholar
• Mahdian R, Nodouzi V, Asgari M, et al. Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer. Mol Biol Rep. 2014;41:6125–6131.
   PubMed Web of Science ®Google Scholar
• Mohsenzadegan M, Shekarabi M, Madjd Z, et al. Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer. Biomarkers Med. 2015;9:391–401.
   PubMed Web of Science ®Google Scholar
• Mohsenzadegan M, Madjd Z, Asgari M, et al. Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis. Cancer Immunol Immunother. 2013;62:1609–1618.
   PubMed Web of Science ®Google Scholar